proxyvotesnow.com

Home › Companies › XENON PHARMACEUTICALS INC. › 2024-2025

XENON PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and XENON PHARMACEUTICALS INC.’s Form 8-K, filed 2025-06-05 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 11Ballot items
  • 207Asset managers
  • 2,073Fund votes
  • 2025-06-04Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore XENON PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by XENON PHARMACEUTICALS INC.

These tallies are XENON PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

XENON PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2025-06-04
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Dawn Svoronos 66,244,0953,593,715-- --2,237,919 Majority: yes
Elect Director: Gillian Cannon 68,942,319895,491-- --2,237,919 Majority: yes
Elect Director: Steven Gannon 69,048,114789,696-- --2,237,919 Majority: yes
Elect Director: Elizabeth Garofalo 68,942,869894,941-- --2,237,919 Majority: yes
Elect Director: Justin Gover 68,866,647971,163-- --2,237,919 Majority: yes
Elect Director: Patrick Machado 64,129,7065,708,104-- --2,237,919 Majority: yes
Elect Director: Ian Mortimer 69,082,169755,641-- --2,237,919 Majority: yes
Elect Director: Gary Patou 68,936,669901,141-- --2,237,919 Majority: yes
Proposal Two – Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay"). 67,252,2002,125,675459,935 --2,237,919 Majority: yes
Proposal Three – Appointment of Auditor. 72,041,362---- 34,3670 Majority: yes
Proposal Four – Remuneration of Auditor. 72,040,09224,83510,802 --0 Majority: yes

Source: XENON PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-06-05 — read the filing on EDGAR.

How asset managers voted at the XENON PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 207 asset managers that disclosed a XENON PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. To approve, on an advisory basis, the compensation of the Corporation's named executive officers;

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 7 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 67,252,200AGAINST: 2,125,675

XENON PHARMACEUTICALS INC.’s own tally for this item (“Proposal Two – Advisory Vote on Compensation of Named Executive Officers ("Say-on-Pay").”): 67,252,200 for, 2,125,675 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,586,359 outstanding shares: 88% for, 3% against (91% of the company cast a for/against vote).

The 206 asset managers below cast 98% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 98%
FOR: 97.5%AGAINST: 1.8%ABSTAIN: 0.5%NOT VOTED: 0.1%
Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Corporation's named executive officers;” at XENON PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity16,405,6270 00For
Capital Group10,800,6080 00For
Avoro Capital Advisors LLC5,741,6660 00For
Wellington3,481,5360 00For
Janus Henderson3,287,1504,726 00For
DRIEHAUS CAPITAL MANAGEMENT LLC3,044,6320 00For
Vanguard2,937,6844 00For
BRAIDWELL LP2,461,1410 00For
Commodore Capital LP2,375,0000 00For
JPMorgan1,870,2550 00For
AllianceBernstein1,591,1090 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.1,544,5700 00For
Affinity Asset Advisors, LLC1,333,5030 00For
PICTET ASSET MANAGEMENT SA1,189,9030 00For
JANUS INVESTMENT FUND1,129,2060 00For
Vestal Point Capital, LP1,125,6480 00For
T. Rowe Price1,091,5050 00For
Loomis Sayles1,006,69945,437 00For
SAMLYN CAPITAL, LLC1,014,6030 00For
Deep Track Capital, LP1,000,0000 00For
WESTFIELD CAPITAL MANAGEMENT CO LP972,8553,660 00For
ORBIMED ADVISORS LLC947,8770 00For
BlackRock936,5890 00For
Rock Springs Capital Management LP927,9500 00For
Aberdeen874,2180 00For

Showing the 25 largest of 206 asset managers. See all 206 in the interactive database.

2. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Dawn Svoronos

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 66,244,095AGAINST: 3,593,715

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dawn Svoronos”): 66,244,095 for, 3,593,715 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,586,359 outstanding shares: 86% for, 5% against (91% of the company cast a for/against vote).

The 62 asset managers below cast 99.7% of the shares they voted on this item FOR (25,556,685 for, 71,365 against).

FOR 99.7%
FOR: 25,556,685 (99.7%)AGAINST: 71,365 (0.3%)
Largest asset managers voting on “To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Mana” at XENON PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,926,4990 00For
Capital Group5,394,1510 00For
Vanguard2,806,6720 00For
JANUS INVESTMENT FUND1,129,2060 00For
Prudential/PGIM686,9970 00For
BlackRock661,5410 00For
DRIEHAUS MUTUAL FUNDS658,8230 00For
JPMorgan622,6650 00For
Bridge Builder Trust499,2600 00For
AllianceBernstein447,1520 00For
Aberdeen437,1090 00For
HARBOR FUNDS399,7590 00For
Loomis Sayles391,2750 00For
T. Rowe Price317,6550 00For
Brinker Capital Destinations Trust316,6790 00For
AB DISCOVERY GROWTH FUND, INC.277,7190 00For
Federated Hermes232,5000 00For
Putnam229,0400 00For
BNY Mellon152,3290 00For
Dimensional134,2510 00For
Invesco133,5070 00For
Equitable120,1690 00For
Goldman Sachs115,3500 00For
Columbia Threadneedle103,6190 00For
BARON SELECT FUNDS100,1000 00For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

3. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Elizabeth Garofalo

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 68,942,869AGAINST: 894,941

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elizabeth Garofalo”): 68,942,869 for, 894,941 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,586,359 outstanding shares: 90% for, 1% against (91% of the company cast a for/against vote).

The 62 asset managers below cast 99.9% of the shares they voted on this item FOR (25,618,454 for, 9,596 against).

FOR 99.9%
FOR: 25,618,454 (100.0%)AGAINST: 9,596 (0.0%)
Largest asset managers voting on “To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Mana” at XENON PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,926,4990 00For
Capital Group5,394,1510 00For
Vanguard2,806,6720 00For
JANUS INVESTMENT FUND1,129,2060 00For
Prudential/PGIM686,9970 00For
BlackRock661,5410 00For
DRIEHAUS MUTUAL FUNDS658,8230 00For
JPMorgan622,6650 00For
Bridge Builder Trust499,2600 00For
AllianceBernstein447,1520 00For
Aberdeen437,1090 00For
HARBOR FUNDS399,7590 00For
Loomis Sayles391,2750 00For
T. Rowe Price317,6550 00For
Brinker Capital Destinations Trust316,6790 00For
AB DISCOVERY GROWTH FUND, INC.277,7190 00For
Federated Hermes232,5000 00For
Putnam229,0400 00For
BNY Mellon152,3290 00For
Dimensional134,2510 00For
Invesco133,5070 00For
Equitable120,1690 00For
Goldman Sachs115,3500 00For
Columbia Threadneedle103,6190 00For
BARON SELECT FUNDS100,1000 00For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

4. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gary Patou

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 68,936,669AGAINST: 901,141

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gary Patou”): 68,936,669 for, 901,141 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,586,359 outstanding shares: 90% for, 1% against (91% of the company cast a for/against vote).

The 62 asset managers below cast 99.9% of the shares they voted on this item FOR (25,618,454 for, 9,596 against).

FOR 99.9%
FOR: 25,618,454 (100.0%)AGAINST: 9,596 (0.0%)
Largest asset managers voting on “To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Mana” at XENON PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,926,4990 00For
Capital Group5,394,1510 00For
Vanguard2,806,6720 00For
JANUS INVESTMENT FUND1,129,2060 00For
Prudential/PGIM686,9970 00For
BlackRock661,5410 00For
DRIEHAUS MUTUAL FUNDS658,8230 00For
JPMorgan622,6650 00For
Bridge Builder Trust499,2600 00For
AllianceBernstein447,1520 00For
Aberdeen437,1090 00For
HARBOR FUNDS399,7590 00For
Loomis Sayles391,2750 00For
T. Rowe Price317,6550 00For
Brinker Capital Destinations Trust316,6790 00For
AB DISCOVERY GROWTH FUND, INC.277,7190 00For
Federated Hermes232,5000 00For
Putnam229,0400 00For
BNY Mellon152,3290 00For
Dimensional134,2510 00For
Invesco133,5070 00For
Equitable120,1690 00For
Goldman Sachs115,3500 00For
Columbia Threadneedle103,6190 00For
BARON SELECT FUNDS100,1000 00For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

5. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Gillian Cannon

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 68,942,319AGAINST: 895,491

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gillian Cannon”): 68,942,319 for, 895,491 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,586,359 outstanding shares: 90% for, 1% against (91% of the company cast a for/against vote).

The 62 asset managers below cast 99.9% of the shares they voted on this item FOR (25,618,454 for, 9,596 against).

FOR 99.9%
FOR: 25,618,454 (100.0%)AGAINST: 9,596 (0.0%)
Largest asset managers voting on “To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Mana” at XENON PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,926,4990 00For
Capital Group5,394,1510 00For
Vanguard2,806,6720 00For
JANUS INVESTMENT FUND1,129,2060 00For
Prudential/PGIM686,9970 00For
BlackRock661,5410 00For
DRIEHAUS MUTUAL FUNDS658,8230 00For
JPMorgan622,6650 00For
Bridge Builder Trust499,2600 00For
AllianceBernstein447,1520 00For
Aberdeen437,1090 00For
HARBOR FUNDS399,7590 00For
Loomis Sayles391,2750 00For
T. Rowe Price317,6550 00For
Brinker Capital Destinations Trust316,6790 00For
AB DISCOVERY GROWTH FUND, INC.277,7190 00For
Federated Hermes232,5000 00For
Putnam229,0400 00For
BNY Mellon152,3290 00For
Dimensional134,2510 00For
Invesco133,5070 00For
Equitable120,1690 00For
Goldman Sachs115,3500 00For
Columbia Threadneedle103,6190 00For
BARON SELECT FUNDS100,1000 00For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

6. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Ian Mortimer

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 69,082,169AGAINST: 755,641

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Ian Mortimer”): 69,082,169 for, 755,641 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,586,359 outstanding shares: 90% for, 1.0% against (91% of the company cast a for/against vote).

The 62 asset managers below cast 99.9% of the shares they voted on this item FOR (25,618,454 for, 9,596 against).

FOR 99.9%
FOR: 25,618,454 (100.0%)AGAINST: 9,596 (0.0%)
Largest asset managers voting on “To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Mana” at XENON PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,926,4990 00For
Capital Group5,394,1510 00For
Vanguard2,806,6720 00For
JANUS INVESTMENT FUND1,129,2060 00For
Prudential/PGIM686,9970 00For
BlackRock661,5410 00For
DRIEHAUS MUTUAL FUNDS658,8230 00For
JPMorgan622,6650 00For
Bridge Builder Trust499,2600 00For
AllianceBernstein447,1520 00For
Aberdeen437,1090 00For
HARBOR FUNDS399,7590 00For
Loomis Sayles391,2750 00For
T. Rowe Price317,6550 00For
Brinker Capital Destinations Trust316,6790 00For
AB DISCOVERY GROWTH FUND, INC.277,7190 00For
Federated Hermes232,5000 00For
Putnam229,0400 00For
BNY Mellon152,3290 00For
Dimensional134,2510 00For
Invesco133,5070 00For
Equitable120,1690 00For
Goldman Sachs115,3500 00For
Columbia Threadneedle103,6190 00For
BARON SELECT FUNDS100,1000 00For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

7. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Justin Gover

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 68,866,647AGAINST: 971,163

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Justin Gover”): 68,866,647 for, 971,163 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,586,359 outstanding shares: 90% for, 1% against (91% of the company cast a for/against vote).

The 62 asset managers below cast 99.9% of the shares they voted on this item FOR (25,618,454 for, 9,596 against).

FOR 99.9%
FOR: 25,618,454 (100.0%)AGAINST: 9,596 (0.0%)
Largest asset managers voting on “To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Mana” at XENON PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,926,4990 00For
Capital Group5,394,1510 00For
Vanguard2,806,6720 00For
JANUS INVESTMENT FUND1,129,2060 00For
Prudential/PGIM686,9970 00For
BlackRock661,5410 00For
DRIEHAUS MUTUAL FUNDS658,8230 00For
JPMorgan622,6650 00For
Bridge Builder Trust499,2600 00For
AllianceBernstein447,1520 00For
Aberdeen437,1090 00For
HARBOR FUNDS399,7590 00For
Loomis Sayles391,2750 00For
T. Rowe Price317,6550 00For
Brinker Capital Destinations Trust316,6790 00For
AB DISCOVERY GROWTH FUND, INC.277,7190 00For
Federated Hermes232,5000 00For
Putnam229,0400 00For
BNY Mellon152,3290 00For
Dimensional134,2510 00For
Invesco133,5070 00For
Equitable120,1690 00For
Goldman Sachs115,3500 00For
Columbia Threadneedle103,6190 00For
BARON SELECT FUNDS100,1000 00For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

8. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Patrick Machado

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%8%
FOR: 64,129,706AGAINST: 5,708,104

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Patrick Machado”): 64,129,706 for, 5,708,104 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,586,359 outstanding shares: 84% for, 7% against (91% of the company cast a for/against vote).

The 62 asset managers below cast 92% of the shares they voted on this item FOR (23,550,634 for, 2,077,416 against).

FOR 92%8%
FOR: 23,550,634 (91.9%)AGAINST: 2,077,416 (8.1%)
Largest asset managers voting on “To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Mana” at XENON PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,926,4990 00For
Capital Group5,394,1510 00For
Vanguard2,806,6720 00For
JANUS INVESTMENT FUND1,129,2060 00For
Prudential/PGIM686,9970 00For
BlackRock661,5410 00For
DRIEHAUS MUTUAL FUNDS658,8230 00For
JPMorgan0622,665 00Against
Bridge Builder Trust499,2600 00For
AllianceBernstein0447,152 00Against
Aberdeen437,1090 00For
HARBOR FUNDS399,7590 00For
Loomis Sayles391,2750 00For
T. Rowe Price317,6550 00For
Brinker Capital Destinations Trust316,6790 00For
AB DISCOVERY GROWTH FUND, INC.0277,719 00Against
Federated Hermes0232,500 00Against
Putnam0229,040 00Against
BNY Mellon152,3290 00For
Dimensional134,2510 00For
Invesco133,5070 00For
Equitable19,107101,062 00Against
Goldman Sachs115,3500 00For
Columbia Threadneedle103,6190 00For
BARON SELECT FUNDS100,1000 00For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

9. To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Management Information Circular to hold office until the next annual meeting of the Corporation or until their successors are duly elected: Steven Gannon

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 69,048,114AGAINST: 789,696

XENON PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Steven Gannon”): 69,048,114 for, 789,696 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,586,359 outstanding shares: 90% for, 1% against (91% of the company cast a for/against vote).

The 62 asset managers below cast 99.9% of the shares they voted on this item FOR (25,618,454 for, 9,596 against).

FOR 99.9%
FOR: 25,618,454 (100.0%)AGAINST: 9,596 (0.0%)
Largest asset managers voting on “To elect as directors of the Corporation the eight nominees named in the accompanying Proxy Statement and Mana” at XENON PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,926,4990 00For
Capital Group5,394,1510 00For
Vanguard2,806,6720 00For
JANUS INVESTMENT FUND1,129,2060 00For
Prudential/PGIM686,9970 00For
BlackRock661,5410 00For
DRIEHAUS MUTUAL FUNDS658,8230 00For
JPMorgan622,6650 00For
Bridge Builder Trust499,2600 00For
AllianceBernstein447,1520 00For
Aberdeen437,1090 00For
HARBOR FUNDS399,7590 00For
Loomis Sayles391,2750 00For
T. Rowe Price317,6550 00For
Brinker Capital Destinations Trust316,6790 00For
AB DISCOVERY GROWTH FUND, INC.277,7190 00For
Federated Hermes232,5000 00For
Putnam229,0400 00For
BNY Mellon152,3290 00For
Dimensional134,2510 00For
Invesco133,5070 00For
Equitable120,1690 00For
Goldman Sachs115,3500 00For
Columbia Threadneedle103,6190 00For
BARON SELECT FUNDS100,1000 00For

Showing the 25 largest of 62 asset managers. See all 62 in the interactive database.

10. To appoint PricewaterhouseCoopers LLP ("PwC") as the Corporation's auditor to hold office until the next annual meeting of the Corporation;

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 72,041,362WITHHELD: 34,367

XENON PHARMACEUTICALS INC.’s own tally for this item (“Proposal Three – Appointment of Auditor.”): 72,041,362 for, 34,367 withheld, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,586,359 outstanding shares: 94% for, 0.1% withheld (94% of the company cast a for/withheld vote).

The 61 asset managers below cast 100% of the shares they voted on this item FOR (25,558,144 for, 0 against).

FOR 99.9%
FOR: 25,558,144 (100.0%)ABSTAIN: 9,596 (0.0%)
Largest asset managers voting on “To appoint PricewaterhouseCoopers LLP ("PwC") as the Corporation's auditor to hold office until the next annua” at XENON PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,926,4990 00For
Capital Group5,394,1510 00For
Vanguard2,806,6720 00For
JANUS INVESTMENT FUND1,129,2060 00For
Prudential/PGIM686,9970 00For
BlackRock661,5410 00For
DRIEHAUS MUTUAL FUNDS658,8230 00For
JPMorgan622,6650 00For
Bridge Builder Trust499,2600 00For
AllianceBernstein447,1520 00For
Aberdeen437,1090 00For
HARBOR FUNDS399,7590 00For
Loomis Sayles391,2750 00For
T. Rowe Price317,6550 00For
Brinker Capital Destinations Trust316,6790 00For
AB DISCOVERY GROWTH FUND, INC.277,7190 00For
Federated Hermes232,5000 00For
Putnam229,0400 00For
BNY Mellon152,3290 00For
Dimensional134,2510 00For
Invesco133,5070 00For
Equitable120,1690 00For
Goldman Sachs115,3500 00For
Columbia Threadneedle103,6190 00For
BARON SELECT FUNDS100,1000 00For

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

11. To authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the auditors of the Corporation;

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 72,040,092AGAINST: 24,835

XENON PHARMACEUTICALS INC.’s own tally for this item (“Proposal Four – Remuneration of Auditor.”): 72,040,092 for, 24,835 against, per its Form 8-K filed 2025-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 76,586,359 outstanding shares: 94% for, 0.1% against (94% of the company cast a for/against vote).

The 61 asset managers below cast 99.9% of the shares they voted on this item FOR (25,558,144 for, 0 against).

FOR 99.9%
FOR: 25,558,144 (100.0%)AGAINST: 0 (0.0%)ABSTAIN: 9,596 (0.0%)
Largest asset managers voting on “To authorize the Audit Committee of the board of directors of the Corporation to fix the remuneration to be pa” at XENON PHARMACEUTICALS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity7,926,4990 00For
Capital Group5,394,1510 00For
Vanguard2,806,6720 00For
JANUS INVESTMENT FUND1,129,2060 00For
Prudential/PGIM686,9970 00For
BlackRock661,5410 00For
DRIEHAUS MUTUAL FUNDS658,8230 00For
JPMorgan622,6650 00For
Bridge Builder Trust499,2600 00For
AllianceBernstein447,1520 00For
Aberdeen437,1090 00For
HARBOR FUNDS399,7590 00For
Loomis Sayles391,2750 00For
T. Rowe Price317,6550 00For
Brinker Capital Destinations Trust316,6790 00For
AB DISCOVERY GROWTH FUND, INC.277,7190 00For
Federated Hermes232,5000 00For
Putnam229,0400 00For
BNY Mellon152,3290 00For
Dimensional134,2510 00For
Invesco133,5070 00For
Equitable120,1690 00For
Goldman Sachs115,3500 00For
Columbia Threadneedle103,6190 00For
BARON SELECT FUNDS100,1000 00For

Showing the 25 largest of 61 asset managers. See all 61 in the interactive database.

Largest XENON PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of XENON PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 76,586,359 shares outstanding at the time of that meeting.

Top XENON PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 21.42%
2Capital Group 14.10%
3Avoro Capital Advisors LLC 7.50%
4Wellington 4.55%
5Janus Henderson 4.30%
6DRIEHAUS CAPITAL MANAGEMENT LLC 3.98%
7Vanguard 3.84%
8BRAIDWELL LP 3.21%
9Commodore Capital LP 3.10%
10JPMorgan 2.44%

Reported XENON PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

XENON PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
FMR (Fidelity) 10.82% 13F
FMR LLC 10.25% DEF14A
Avoro Capital Advisors LLC 7.40% DEF14A
Driehaus Capital Management LLC 5.67% DEF14A
JANUS HENDERSON GROUP PLC 5.45% 13G
Entities affiliated with Wellington Management Group LLP 5.44% DEF14A
Wellington Management 4.95% 13F
Capital International 4.03% 13F
BlackRock 2.66% 13F
Ian Mortimer 1.93% DEF14A

Percentages above are of 76,586,359 shares outstanding, as reported by XENON PHARMACEUTICALS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from XENON PHARMACEUTICALS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At XENON PHARMACEUTICALS INC.'s shareholder meeting held 2025-06-04, in the 2024-2025 proxy season, 207 asset managers reported how they voted on 11 ballot items in their SEC Form N-PX filings, covering 2,073 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Corporation's named executive… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: XENON PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-05.

XENON PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.